There are many situations where intermittent short-term exposures of a certain kind are thought to temporarily enhance the risk of onset of an adverse health event (illness). When the hazard rate of the illness is small it is desirable to investigate this possible association using only data on cases occurring in a finite observation period. Here we extend a method for such an analysis by allowing the baseline hazard for the illness to depend on the increasing age over the observation period and using age at the times of exposure, a time dependent variable, as a covariate in the effect of the transient exposure. The method is illustrated with a study of the possible association of long-haul air travel and hospitalization for venous thromboembolism over an observation period of 19 years. It is demonstrated that allowing for aging over the observation period can avoid bias in the estimated effect size when the baseline hazard for the illness increases with age and exposures occur irregularly over time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/biostatistics/5.2.239 | DOI Listing |
J Med Microbiol
January 2025
Parul Institute of Applied Sciences, Faculty of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India.
The rise in antimicrobial resistance poses a significant threat to global health, particularly among diabetic patients who are prone to urinary tract infections (UTIs). Pathogens that cause UTI among diabetic patients exhibit significant multidrug resistance (MDR) patterns, necessitating more precise empirical treatment strategies..
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Department of Rural Clinical Science, La Trobe Rural Health School, La Trobe University, Melbourne, Australia.
Objective: To compare the salivary profiles of smokers (e-cigarette smokers, e-cigarette and former conventional cigarette smokers, dual users, and conventional cigarette smokers) and non-smokers in adolescents, focusing on acidity level, flow rate, viscosity, as well as the quantity of Streptococcus mutans, Porphyromonas gingivalis, and Candida albicans.
Methods: This analytical observational study, with a cross-sectional design, involves collecting saliva samples from five groups through the draining method. Saliva viscosity was assessed visually, while saliva flow rate was monitored over a ten-minute period.
Asian Pac J Cancer Prev
January 2025
Center Incharge, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.
Purpose: This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.
Methods: The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology.
Asian Pac J Cancer Prev
January 2025
Department of Medical Oncology, RGCI&RC, Delhi, India.
Background: Human Lung Carcinoma (LC) is among the most diagnosed cancers across the world among those non-small cell lung cancer (NSCLC) comprises about 85%. Next Generation Sequencing based detection of mutations are now well established in molecular oncology. With the advent of modern diagnostic methods, it is now well known that there are several mutations and gene rearrangements which are associated with the development of LC.
View Article and Find Full Text PDFInt J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!